M.D. Sass Investors Services Inc. acquired a new stake in Charles River Laboratories Intl. Inc (NYSE:CRL) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 46,380 shares of the medical research company’s stock, valued at approximately $6,582,000. Charles River Laboratories Intl. makes up 1.5% of M.D. Sass Investors Services Inc.’s investment portfolio, making the stock its 26th largest holding. M.D. Sass Investors Services Inc. owned approximately 0.10% of Charles River Laboratories Intl. at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Bank of New York Mellon Corp boosted its position in Charles River Laboratories Intl. by 49.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 978,183 shares of the medical research company’s stock valued at $138,804,000 after buying an additional 323,625 shares during the period. AQR Capital Management LLC raised its stake in shares of Charles River Laboratories Intl. by 18.0% in the first quarter. AQR Capital Management LLC now owns 2,082,761 shares of the medical research company’s stock valued at $301,042,000 after acquiring an additional 317,001 shares in the last quarter. OZ Management LP purchased a new position in Charles River Laboratories Intl. in the first quarter valued at $44,308,000. DekaBank Deutsche Girozentrale boosted its holdings in Charles River Laboratories Intl. by 18,244.4% in the first quarter. DekaBank Deutsche Girozentrale now owns 241,596 shares of the medical research company’s stock valued at $29,368,000 after purchasing an additional 240,279 shares during the period. Finally, King Luther Capital Management Corp grew its stake in Charles River Laboratories Intl. by 179.0% during the 2nd quarter. King Luther Capital Management Corp now owns 343,777 shares of the medical research company’s stock worth $48,782,000 after purchasing an additional 220,562 shares in the last quarter. 94.40% of the stock is currently owned by hedge funds and other institutional investors.

Several equities research analysts have weighed in on the company. ValuEngine downgraded Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Leerink Swann started coverage on Charles River Laboratories Intl. in a research report on Monday, June 10th. They set an “outperform” rating for the company. Svb Leerink assumed coverage on shares of Charles River Laboratories Intl. in a research note on Monday, June 10th. They set an “outperform” rating and a $155.00 target price on the stock. Finally, Zacks Investment Research cut shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a report on Monday. Seven investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $147.62.

Charles River Laboratories Intl. stock traded up $0.63 during mid-day trading on Wednesday, reaching $130.31. 18,952 shares of the company were exchanged, compared to its average volume of 233,653. The firm has a market cap of $6.35 billion, a PE ratio of 21.62, a price-to-earnings-growth ratio of 1.66 and a beta of 1.09. The company has a debt-to-equity ratio of 1.47, a quick ratio of 1.38 and a current ratio of 1.59. The firm’s 50-day simple moving average is $132.09 and its two-hundred day simple moving average is $136.35. Charles River Laboratories Intl. Inc has a twelve month low of $103.00 and a twelve month high of $149.07.

Charles River Laboratories Intl. (NYSE:CRL) last issued its quarterly earnings results on Wednesday, July 31st. The medical research company reported $1.63 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.55 by $0.08. Charles River Laboratories Intl. had a return on equity of 22.01% and a net margin of 8.94%. The firm had revenue of $657.60 million during the quarter, compared to the consensus estimate of $662.61 million. During the same period last year, the company earned $1.62 earnings per share. The company’s revenue for the quarter was up 12.4% on a year-over-year basis. As a group, equities research analysts anticipate that Charles River Laboratories Intl. Inc will post 6.52 EPS for the current year.

In other Charles River Laboratories Intl. news, insider David Ross Smith sold 1,249 shares of the company’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $130.36, for a total transaction of $162,819.64. Following the completion of the transaction, the insider now owns 19,327 shares in the company, valued at approximately $2,519,467.72. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.80% of the stock is currently owned by corporate insiders.

Charles River Laboratories Intl. Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Story: What are the advantages of the Stochastic Momentum Index?

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.